Drug Profile
BMS 833923
Alternative Names: BMS-833923; XL-139Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Exelixis
- Developer Bristol-Myers Squibb; Exelixis
- Class Antineoplastics; Small molecules
- Mechanism of Action Hedgehog cell-signalling pathway inhibitors; SMO protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastrointestinal cancer; Multiple myeloma; Small cell lung cancer; Solid tumours
- Discontinued Chronic myeloid leukaemia
Most Recent Events
- 15 Sep 2020 Discontinued - Phase-I/II for Chronic myeloid leukaemia (Combination therapy, Second-line therapy or greater) in United Kingdom, Italy, Germany, Finland, Canada, USA, France (PO) before September 2020
- 15 Sep 2020 Discontinued - Phase-II for Chronic myeloid leukaemia (Combination therapy, First-line therapy, Newly diagnosed) in Germany, Canada, USA, Spain, Poland, Finland, Belgium, Argentina, France (PO) before September 2020
- 01 Jan 2017 Bristol-Myers Squibb terminates a phase II trial as no participants enrolled in this trial could receive the recommended phase 2 dose in Chronic myeloid leukaemia (Newly diagnosed, First-line therapy, Combination therapy) in USA, Argentina, Belgium, Canada, Finland, France, Germany, Poland and Spain (NCT01357655)